
Our Story
ImmixBio was founded in 2012 by a visionary physician/scientist, a world-renown pharmacology expert, a seasoned biotechnology patent attorney and an impact-driven founding family office. We are developing an entirely new class of Tissue-Specific Therapeutics, or TSTx, which we believe will replace first-line therapies across a multitude of cancer indications.
Unfortunately, many of us have experienced losing a loved one to cancer. Our team are not just experts in their fields, we have also been personally affected by this disease. With this deeply personal impetus, ImmixBio’s objective is a meaningful benefit for each patient – nothing short. In memory of Donald E. Senn, Ph.D. who tragically lost his life to cancer at the height of a vibrant career as a biomedical scientist, and to all cancer patients and families around the world who continue their brave fight.
Management



Ilya Rachman, MD PhD
Gabriel Morris, BA
Graham Ross, FFPM
Co-Founder &
Chief Executive Officer
Dr. Rachman is a physician/scientist and former community clinical faculty...
Chief Financial Officer
Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris...
Chief Medical Officer &
Head of Clinical Development
Dr. Ross is an experienced pharmaceutical physician executive with a successful...

Ilya Rachman, MD PhD
Co-Founder &
Chief Executive Officer

Gabriel Morris, BA
Chief Financial Officer

Graham Ross, FFPM
Chief Medical Officer &
Head of Clinical Development
Board of Directors
Helen C. Adams, CPA
Jane Buchan, PhD
Jason Hsu, PhD
Magda Marquet, PhD
Carey Ng, PhD
Ilya Rachman, MD, PhD
Gabriel Morris
Helen C. Adams, CPA
Jane Buchan, PhD
Jason Hsu, PhD
Magda Marquet, PhD
Carey Ng, PhD
Ilya Rachman, MD, PhD
Gabriel Morris
Scientific Advisory Board
Larry Norton, MD
Sant Chawla, MD
Razelle Kurzrock, MD
Galit Lahav, PhD
Gary Schiller, MD
George W. Sledge, MD
Larry Norton, MD
Sant Chawla, MD
Razelle Kurzrock, MD
Galit Lahav, PhD
Gary Schiller, MD
George W. Sledge, MD
Vladimir Torchilin,
Ph.D, D.Sc., MSE
Sean Senn, JD, MS
Co-Founder
Dr. Torchilin is also a University Distinguished Professor of Pharmaceutical Sciences....
Co-Founder
Sean Senn is a Co-Founder of Immix and a practicing biotechnology patent attorney.....
Vladimir Torchilin, Ph.D, D.Sc., MSE
Co-Founder
Dr. Torchilin is also a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology...
Sean Senn, JD, MS
Co-Founder
Sean Senn is a Co-Founder of Immix and a practicing biotechnology patent attorney, with graduate degrees in Molecular Biology and an MBA from UCLA...
Director
Ms. Adams is also the Audit Committee Chair and a member of the board of directors of Prometheus Biosciences, Inc (Nasdaq:RXDX). From January 2013 to March 2018, Ms. Adams was the San Diego Area Managing Partner for Haskell & White LLP, a regional certified public accounting firm. Previously, Ms. Adams was a certified public accountant at Deloitte & Touche LLP from 1982 to 2009, serving most recently as a Partner in the Life Sciences and Technology Group. From 2010 to 2013, Ms. Adams was a member of the board of directors of Genasys Inc. (formerly known as LRAD Corporation), serving as the Audit Committee Chair and member of the Compensation Committee. In addition to her public company board service, Ms. Adams has served on the boards of directors and working committees of many organizations, including Athena San Diego, the Athena Foundation, Corporate Directors’ Forum, Make A Wish San Diego, the YWCA, and the California State University at San Marcos Foundation. Ms. Adams received her BS from San Diego State University and completed an Executive Management Program at Columbia Business School. Ms. Adams’ experience in public accounting and the life sciences industry qualifies her to serve on our board of directors.
Director
Dr. Buchan is also a member of the board of directors of Globe Life Inc (NYSE:GL) and AGF Management Ltd. (TSX:AGF.B) . Dr. Buchan is Chief Executive Officer of Martlet Asset Management, a private investment office established in 2018. Prior to founding Martlet, Dr. Buchan was Chief Executive Officer of PAAMCO, a fund of hedge funds, which she helped found in 2000, and Co-CEO of the holding company, PAAMCO Prisma Holdings. Under her leadership, the firm grew to $32 billion in assets under management. Dr. Buchan began her career at J.P. Morgan Investment Management in the Capital Markets Group. She has been an Assistant Professor of Finance at the Amos Tuck School of Business at Dartmouth. She recently served as chairwoman of the board for the Chartered Alternative Investment Analyst Association (CAIA) and is a member of the Advisory Board for the Master of Financial Engineering Program at UCLA Anderson School of Management. She is a Trustee of Reed College, Portland, Oregon and University of California Irvine Foundation. Dr. Buchan has been actively involved in initiatives to advance the careers of women in finance and is a founding Angel for 100 Women in Finance. has also been recognized with numerous industry honors and awards. She earned a BA in Economics from Yale University and holds both a PhD and an MA in Business Economics (Finance) from Harvard University.
Director
Mr. Hsu is the founder and chairman of Rayliant Global Advisors, a professor of finance at University of California at Los Angeles (UCLA), and on the Board of Advisors for UCLA Anderson School of Management. Rayliant is an asset manager focused on generating alpha from investing in China and other inefficient emerging markets, which has a total of USD 27 billion of investment assets using its strategies across equity, fixed income and alternatives. Prior to founding Rayliant, Mr. Hsu was the co-founder and Chief Investment Officer of Research Affiliates, a quantitative fund manager with over $200 billion under management. Mr. Hsu has received 3 JPM Fabozzi-Bernstein Outstanding Research Awards, 3 CFA Institute Graham and Dodd awards, 3 William Sharpe Best Research awards, 2010 Rising Star of Hedge Fund, 40+ Journal publications and 11+ books and book chapters on investing, 2009 Outstanding Service Award (UCLA Anderson), and has held visiting positions at UC Irvine, National Taiwan Chengchi University, Kyoto University and Tsinghua University. Mr. Hsu received his BS (summa cum laude) from the California Institute of Technology, was awarded a MS from Stanford University, and earned his PhD in finance from UCLA.
Director
Dr. Marquet is also a member of the board of directors of AnaptysBio, Inc. (Nasdaq:ANAB) and Arcturus Therapeutics (Nasdaq:ARCT). She was the co-CEO of Althea Technologies from 2000 to 2008. She is currently the co-CEO of Alma Life Sciences. LLC, an investment and consulting firm and serves on several Boards of Directors. Dr. Marquet has built, led and commercialized multiple life science companies. She is the co-founder of AltheaDx, a commercial stage, precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression, and ALMA Life Sciences, LLC, an early stage investment firm creating and growing innovative healthcare companies. Dr. Marquet co-founded Althea Technologies and, as its co-CEO with full P&L responsibility, led the company to become a leader in the field and a highly profitable, commercial company. As a result, she guided Althea to acquisition by Ajinomoto, a global Japanese company and leader in amino acid technology. Prior to starting Althea Technologies, Dr. Marquet held several positions in pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals. Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. She has received numerous prestigious awards throughout her career including the 2005 Regional Ernst & Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.
Director
Dr. Ng is a Managing Director of Mesa Verde Venture Partners and Member of the Investment Committee. Dr. Ng has over fifteen years investment and operating experience in the biomedical industry, ranging from biotech startups to large biopharmaceutical companies. Dr. Ng serves on the board of a number of Mesa Verde portfolio companies including Immix Biopharma, Elysium Therapeutics, Satiogen Pharmaceuticals (spinout acquired by Shire), Biscayne Neurotherapeutics (acquired by Supernus), and Paradigm (acquired by Exact Sciences). His board observer roles include Matrisys Bioscience, Immusoft, Alastin Skincare, Retrosense Therapeutics (acquired by Allergan), and Oncternal Therapeutics (ONCT). Prior to Mesa Verde, he worked with a number of biomedical startups and was also in business development at Abbott. Dr. Ng has a Ph.D. from UCLA and a MBA from UC San Diego.
Chief Executive Officer, Director
Dr. Rachman is a physician/scientist and former community clinical faculty at UCLA. He received both his MD and PhD from the University of Illinois, and his MBA from UCLA Anderson. Ilya founded a Clinical Research organization that conducted clinical trials of pharmaceutical drugs, and is also currently the CEO of Immix Biopharma, Inc. He has completed several clinical trials as a Principal Investigator and developed strong relationships in the clinical research industry.
Chief Financial Officer, Director
Gabriel Morris is the Chief Financial Officer of Immix Biopharma, Inc. Mr. Morris has been managing partner of Alwaysraise LLC, a life sciences advisory and investment firm based in San Francisco, since founding. Prior, Mr. Morris was the interim Chief Financial Officer of Zap Surgical Systems, a brain radiosurgery company, where he completed a growth equity financing round. Prior, Mr. Morris led cross-border mergers & acquisitions transactions at Goldman Sachs and other global investment banks for more than a decade, where he participated in greater than $50 billion in completed transactions. Mr. Morris received his B.A. from the Columbia University in the City of New York.
Chief Medical Officer & Head of Clinical Development
Dr. Ross is an experienced pharmaceutical physician executive with a successful track record of development and post-marketing activities of a number of cancer therapeutics (including topoisomerase inhibitors and therapeutic antibodies, such as immune checkpoint inhibitors and next generation immunotherapeutics). Prior, Dr. Ross was Senior Medical Science Director, AstraZeneca and Global Clinical Leader at Roche Pharmaceuticals, where he was responsible for the clinical development and registration of pertuzumab in breast cancer indications (marketed as PERJETA® by Roche). Prior to Roche, Dr. Ross was Director of Clinical Development at GlaxoSmithKline for a decade. Dr. Ross trained in oncology in Durban, South Africa and specialized a second time as a pharmaceutical physician in the UK.
Co-Founder
Dr. Torchilin is also a University Distinguished Professor of Pharmaceutical Sciences and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. Prior to Northeastern, Dr. Torchilin was Massachusetts General Hospital/Harvard Medical School Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Dr. Torchilin’s interests include drug delivery and targeting, nanomedicine, multifunctional and stimuli-sensitive pharmaceutical nanocarriers, biomedical polymers, experimental cancer therapy. Dr. Torchilin has published more than 400 original papers, more than 150 reviews and book chapters, wrote and edited 12 books, and holds more than 40 patents. Google Scholar shows more than 52,000 citations of his papers with H-index of 102. Dr. Torchilin is Editor-in-Chief of Current Drug Discovery Technologies, Drug Delivery, and OpenNano, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many other journals. Dr. Torchilin received more than $30 M from the governmental and industrial sources in research funding. Dr. Torchilin has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010. Dr. Torchilin received his Ph.D. and D.Sc. in Polymer Chemistry, and MS in Chemistry from Moscow State University.
Co-Founder
Sean Senn is a Co-Founder of Immix and a practicing biotechnology patent attorney, with graduate degrees in Molecular Biology and an MBA from UCLA Anderson. He was previously a Partner at the law firm of Archer Norris, PLC, where he Chaired the Patent Practice Group. Previous to this, he was with Nixon Peabody as a patent attorney. Mr. Senn works with biotech-based companies across a wide range of matters and supports technology transfer programs at academic institutions such as Stanford University and the Regents of the University of California. Sean represents clients in patent procurement, licensing, and coordination of complex research arrangements.
Chair, Scientific Advsiory Board
Dr. Norton is Senior Vice President, Office of the President, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill-Cornell Medical College. He is a founder and Scientific Director of the Breast Cancer Research Foundation. Dr. Norton is the founding incumbent of the Norna S. Sarofim Chair of Clinical Oncology at MSKCC and a Professor of Medicine in the Weill Cornell Мedical College. He was a U.S. Presidential appointee to the National Cancer Advisory Board (the board of directors of the NCI) serving as Chair of the Budget Sub-Committee. A former Director of the American Society of Clinical Oncology, he served as President of ASCO and ubsequently Chair of the ASCO Foundation, now the Conquer Cancer Foundation. He has been Vice-Chair of the Lymphoma Committee and a long-serving Chair of the Breast Committee of the Cancer and Leukemia Group B (now the Alliance for Clinical Trials in Oncology). He has served on or chaired numerous committees of the National Cancer Institute, National Institutes of Health, and the Institute of Medicine of the National Academy of Sciences. He is an editorial board member or reviewer for numerous medical journals and on the advisory boards of many advocacy and medical institutions including the Cold Spring Harbor Laboratory Cancer Center and several Specialized Programs of Research Excellence. Dr. Norton’s personal research has focused on the use of medicines to treat cancer, particularly the application of mathematical methods to optimizing dose and schedule. He has been involved in the development of several effective agents including paclitaxel and trastuzumab. He co-invented the Norton-Simon Model of cancer growth which has broadly influenced cancer therapy, and more recently the self-seeding concept of cancer metastasis and growth. He is the Principal Investigator of an NCI Program Project Grant in Models of Human Breast Cancer and an author of more than 350 published articles and many book chapters. He received his AB with Highest Distinction from the University of Rochester and his MD from the College of Physicians and Surgeons of Columbia University. He trained in medicine and medical research at the Albert Einstein College of Medicine and the National Cancer Institute (NCI).
Scientific Advisor
Dr. Chawla holds medical licensures in both Texas and California, and he is board certified in Internal Medicine and Medical Oncology He is a pioneering physician whose work in sarcoma oncology has brought him several accolades and recognition as one of the world’s leading authorities in medical treatment and clinical research for bone and soft-tissue sarcomas and sarcoma therapy. Dr. Chawla heads the Sarcoma Oncology Center in Santa Monica, CA. Dr. Chawla serves on the clinical faculty of numerous prestigious cancer centers, including UCLA, USC, John Wayne Cancer Institute at St. John’s Hospital; he has been an adjunct associate professor at Stanford University and is an adjunct associate professor at the University of Texas, M.D. Anderson Cancer Center; and he is a medical oncologist at Cedars Sinai Comprehensive Cancer Center. Over his 30 years of medical and clinical research experience, Dr. Chawla’s research has been a foundation for further breakthroughs in cancer treatment. Dr. Chawla received his medical degree and completed his residency training in Internal Medicine at the All India Institute of Medical Sciences in New Delhi
Scientific Advisor
Dr. Kurzrock joined University of California San Diego Moores Cancer Center in November 2012 as Senior Deputy Center Director for Clinical Science. She is also the Murray Professor of Medicine, Director of the Clinical Trials Office and, on July 1, 2014, became the Chief of the Division of Hematology-Oncology Division (in the UC San Diego School of Medicine) . Dr. Kurzrock’s charge includes growing and innovating the clinical trials program, and heading the newly established Center for Personalized Cancer Therapy and the UCSD Moores Cancer Center Clinical Trials Office. Dr. Kurzrock is best known for successfully creating and chairing the largest Phase I clinical trials department in the world while at the University of Texas M.D. Anderson Cancer Center. Dr. Kurzrock’s unique approach emphasizes using cutting-edge molecular profiling technologies to match patients with novel targeted therapies, reflecting a personalized strategy to optimize cancer treatment. Dr. Kurzrock has served as the Principal Investigator (PI) on more than 90 clinical trials, and overseen over 300 trials, mainly using novel targeted molecules, several of which have gone on to FDA approval. She has published over 500 peer-reviewed articles in a variety of elite medical journals. In addition, she is Chair of the Southwest Oncology Group (SWOG) Early Therapeutics Committee and on their Board of Governors and also serves on the Board of Directors for NCCN and for WIN (World-Wide Innovative Network for Personalized Cancer Therapy). She Chairs the Molecular Diagnostic Clinical Trials committee for the American Association of Cancer Institutes, as well as the Clinical Investigator Committee for NCCN, and the Clinical Trials Committee for WIN. Dr Kurzrock has been the PI of numerous grants and funding awards totaling over 50 million dollars. Dr. Kurzrock received her MD degree from the University of Toronto.
Scientific Advisor
Dr. Lahav is the Novartis Professor of Systems Biology and Department Chair, Systems Biology at Harvard Medical School. Dr. Lahav leads a department at Harvard that uses the power of systems thinking, across macro and micro scales, to unlock new insights into health and disease. Dr. Lahav’s goal is to determine why human cancer cells often show different responses to the same treatment, and to identify new therapies that will increase the efficacy of anti-cancer drugs. Dr. Lahav’s research program works across traditional disciplinary boundaries. Dr. Lahav’s lab has pioneered computational and quantitative experimental approaches to studying the fate and behavior of human cells in disease and health at the single-cell level. Dr. Lahav’s work has yielded critical insights into the function and behavior of tumor-suppressing mechanisms and their role in cellular destiny. Dr. Lahav has been recognized through several awards and honors including the Smith Family Award, Vilcek Prize for Creative Promise, and Excellence in Teaching and Mentoring awards. Dr. Lahav has established and organized leadership and management workshops for postdocs and faculty, as well as developed programs for advancing women in science. Dr. Lahav received her PhD in 2001 from the Technion, Israel Institute of Technology. In 2003, she completed her postdoctoral fellowship at the Weizmann Institute of Science in Israel. She then spent a year at Harvard’s Bauer Center for Genomics Research, and in 2004 joined the Department of Systems Biology at Harvard Medical School. In 2018 Lahav became the Chair of the Department of Systems Biology.
Scientific Advisor
Dr. Schiller is a well-published clinical investigator in acute and chronic leukemias, multiple myeloma, and other hematologic malignancies, as well as in stem cell and bone marrow transplantation. He lectures extensively, and has also written for the popular press. He is Immediate-Past Chairman of the Los Angeles Museum of the Holocaust. His research projects include clinical studies of new drugs, therapies, and bone marrow/stem cell transplantation for patients with malignancies of the blood or bone marrow such as leukemia, multiple myeloma, and lymphoma. He has carried out studies of stem cell transplantation following high-dose chemotherapy and radiation for acute myelogenous leukemia, one of the most common types of leukemia in adults. He has ongoing studies using new drugs and therapeutics for acute and chronic lymphocytic leukemia, acute and chronic myelogenous leukemia, and multiple myeloma; he also has studies going on in certain kinds of non-Hodgkin’s lymphoma and Sickle Cell Anemia. Dr. Schiller received his MD from the USC School of Medicine.
Scientific Advisor
Dr. George W. Sledge, Jr., M.D. is Professor and former Chief of Medical Oncology at Stanford University Medical Center. Dr. Sledge served as a Ballve-Lantero Professor of Oncology of Medicine and Pathology of Indiana University School of Medicine. He served as Co-Director of the breast cancer program at the Indiana University Cancer Center, where he was a Professor of Medicine and Pathology at the Indiana University Simon Cancer Center. Dr. Sledge specializes in the study and treatment of breast cancer and directed the first large, nationwide study on the use of paclitaxel to treat advanced breast cancer. His recent research focuses on novel biologic treatments for breast cancer. He served as a Professor of Indiana University Cancer Center Breast Cancer Program. He has also served as the chair of ASCO’s Education Committee, as a member of the Department of Defense Breast Cancer Research Program’s Integration Panel, as a member of the Food and Drug Administration’s Oncology Drug Advisory Committee (ODAC), and as a member of the External Advisory Committee for The Cancer Genome Atlas (TCGA) project. Dr. Sledge was awarded the Hope Funds for Cancer Research 2013 Award of ‘Excellence for Medicine’. He holds a B.A. from the University of Wisconsin and an M.D. from Tulane University